LDN & peptides

For a sufferer willing to go beyond the standard toolkit, two experimental options come up constantly. One — low-dose naltrexone — is cheap, safe-ish, and genuinely interesting. The other — peptides — is where the marketing badly outruns the evidence.

Low-dose naltrexone (LDN)

The interesting experiment: LDN is a tiny dose (1.5–4.5 mg at night) of an addiction drug, used off-label to calm the immune system. It's cheap, generally safe, and can be layered onto your thyroid medication. Honest evidence: there are no Hashimoto's trials — the enthusiasm comes from clinician reports and better (if still weak) data in other autoimmune conditions and fibromyalgia, and the one large real-world thyroid dataset didn't show reduced medication need. A reasonable supervised experiment for stubborn antibodies or symptoms — soft evidence, not a proven therapy, and recheck your thyroid labs after starting (it can occasionally lower your levothyroxine needs). Evidence ●●○○○

Peptides — the candid answer

Marketing ahead of science: The peptides sold for autoimmunity — thymosin alpha-1, BPC-157, thymosin beta-4 — have the most plausible rationale in thymosin (a genuine immune modulator), but no published Hashimoto's trials for any of them; the rest is rodent data and theory. They're injectable, largely unregulated gray-market products of variable purity, and expensive. Interesting biology — but you'd be the experiment, and it's not where to spend first. Evidence ○○○○○ in Hashimoto's

LDN over injectables — and always re-test

Of the two, LDN is the far safer, cheaper, better-reasoned experiment — do it with a clinician and re-test your thyroid afterward. Gray-market injectable peptides carry real purity and safety risks with no Hashimoto's evidence behind them.

The Hashimoto’s Guide